Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment

The combination of lopinavir/ritonavir remains one of the first-line therapies for the initial antiretroviral regimen in pediatric HIV-infected children. However, the implementation of this recommendation has faced many challenges due to cold-chain requirements, high alcohol content, and unpalatability for ritonavir-boosted lopinavir syrup. In addition, the administration of crushed tablets has shown a detriment for the oral bioavailability of both drugs. Therefore, there is a clinical need to develop safer and better formulations adapted to children's needs. This work has demonstrated, for the first time, the feasibility of using direct powder extrusion 3D printing to manufacture personalized pediatric HIV dosage forms based on 6 mm spherical tablets. H-bonding between drugs and excipients (hydroxypropyl methylcellulose and polyethylene glycol) resulted in the formation of amorphous solid dispersions with a zero-order sustained release profile, opposite to the commercially available formulation Kaletra, which exhibited marked drug precipitation at the intestinal pH.

Automated summary

The combination of lopinavir/ritonavir is commonly used for treating pediatric HIV-infected children. However, challenges arise in implementing this therapy due to storage requirements, high alcohol content, and unpalatability of the medication. This study demonstrated the feasibility of using 3D printing to manufacture personalized pediatric HIV dosage forms.